Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $150.00

Merck & Co., Inc. (NYSE:MRK) had its price target increased by Barclays from $140.00 to $150.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have an overweight rating on the stock.

Several other equities analysts have also issued reports on the stock. UBS Group boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Monday, April 13th. BMO Capital Markets increased their target price on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a report on Monday, July 13th. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $112.00 to $113.00 and gave the company an “equal weight” rating in a research report on Thursday, July 9th. Bank of America lifted their price target on shares of Merck & Co., Inc. from $130.00 to $141.00 and gave the company a “buy” rating in a research note on Tuesday, June 30th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research note on Monday, July 6th. Thirteen research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company. According to data from MarketBeat.com, Merck & Co., Inc. currently has an average rating of “Moderate Buy” and a consensus target price of $134.50.

Merck & Co., Inc. Price Performance

Shares of MRK stock opened at $130.49 on Wednesday. Merck & Co., Inc. has a 52 week low of $77.53 and a 52 week high of $135.05. The stock has a market capitalization of $322.28 billion, a PE ratio of 36.76, a PEG ratio of 5.15 and a beta of 0.19. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.06 and a current ratio of 1.30. The stock’s fifty day moving average is $123.17 and its 200-day moving average is $118.46.

Merck & Co., Inc. (NYSE:MRK) last released its quarterly earnings results on Thursday, April 30th. The company reported ($1.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.47) by $0.19. The business had revenue of $16.29 billion during the quarter, compared to analysts’ expectations of $15.85 billion. Merck & Co., Inc. had a return on equity of 27.55% and a net margin of 13.59%.The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. During the same period in the previous year, the business posted $2.22 earnings per share. Equities research analysts expect that Merck & Co., Inc. will post 2.74 EPS for the current fiscal year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be given a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is 95.77%.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the company. Somerset Trust Co lifted its position in shares of Merck & Co., Inc. by 0.9% during the second quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock worth $1,118,000 after purchasing an additional 81 shares during the last quarter. Stonebridge Financial Group LLC increased its stake in Merck & Co., Inc. by 0.9% in the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock worth $1,124,000 after buying an additional 81 shares during the period. Stronghold Wealth Management L.L.C. increased its stake in Merck & Co., Inc. by 2.6% in the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock worth $416,000 after buying an additional 82 shares during the period. Lederer & Associates Investment Counsel CA lifted its holdings in Merck & Co., Inc. by 0.9% during the 2nd quarter. Lederer & Associates Investment Counsel CA now owns 9,603 shares of the company’s stock valued at $1,234,000 after buying an additional 84 shares in the last quarter. Finally, Pine Haven Investment Counsel Inc lifted its holdings in Merck & Co., Inc. by 0.6% during the 2nd quarter. Pine Haven Investment Counsel Inc now owns 14,273 shares of the company’s stock valued at $1,834,000 after buying an additional 86 shares in the last quarter. Institutional investors own 76.07% of the company’s stock.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck’s launch of subcutaneous Keytruda, known as Qlex, and other lifecycle extensions could preserve the drug’s commercial momentum and support exclusivity through 2039. Recent regulatory approvals, pipeline progress and the acquisitions of Terns and Cidara also broaden the company’s oncology and virology prospects. Merck: Heading Into Q2 Earnings, The Keytruda Cliff Looks Increasingly Less Steep
• Positive Sentiment: Analyst estimates have improved, including Erste Group’s modest increase in its FY2027 EPS forecast to $9.54 from $9.52. Barclays has also forecast strong potential appreciation for MRK, reinforcing the constructive sentiment around the shares. Barclays Forecasts Strong Price Appreciation for Merck & Co., Inc. Stock
• Positive Sentiment: Merck declared a quarterly dividend of $0.85 per share, payable October 7 to shareholders of record September 15. The dividend provides ongoing income support, with a reported annualized yield of about 2.6%.
• Neutral Sentiment: MRK is scheduled to release second-quarter 2026 results before the market opens on August 4. Consensus calls for approximately $16.33 billion in sales and a loss of $0.26 per share, with acquisition costs likely affecting reported earnings. Investors will watch Keytruda demand, Gardasil performance and management’s outlook. Should You Buy, Sell or Hold Merck Stock Ahead of Q2 Earnings?
• Neutral Sentiment: Merck and Wellcome’s Hilleman Laboratories are preparing an experimental Ebola vaccine for clinical trials. The initiative supports Merck’s public-health profile but is unlikely to materially affect near-term financial results. Merck, Wellcome Partner With Global Health Group to Make Ebola Vaccine for Clinical Trials
• Negative Sentiment: After a roughly 17% rally since its latest quarterly results, MRK may already reflect much of the favorable Keytruda and pipeline news. Analysts characterize its longer-term valuation as justified rather than clearly inexpensive, while Gardasil weakness and the approaching earnings event remain risks. Merck Stock Looks Cheap on Cash Flow but Fair on Earnings

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.